Bausch Health Companies Inc (NYSE:BHC) EVP Christina Ackermann sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $22.45, for a total transaction of $76,734.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Christina Ackermann also recently made the following trade(s):

  • On Thursday, July 11th, Christina Ackermann sold 3,968 shares of Bausch Health Companies stock. The stock was sold at an average price of $24.81, for a total transaction of $98,446.08.

Shares of NYSE:BHC traded up $0.39 during trading on Tuesday, reaching $22.69. 2,352,996 shares of the company traded hands, compared to its average volume of 3,925,029. The company has a fifty day simple moving average of $23.95. The firm has a market cap of $7.80 billion, a price-to-earnings ratio of 5.64, a P/E/G ratio of 0.27 and a beta of 0.76. Bausch Health Companies Inc has a 1-year low of $17.20 and a 1-year high of $28.45. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 8.94.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.03). The company had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.15 billion. Bausch Health Companies had a negative net margin of 10.88% and a positive return on equity of 52.12%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period last year, the business earned $0.93 EPS. As a group, research analysts anticipate that Bausch Health Companies Inc will post 4.22 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Citizens Financial Group Inc RI acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at $28,000. Investors Research Corp lifted its stake in shares of Bausch Health Companies by 85.7% in the 2nd quarter. Investors Research Corp now owns 1,300 shares of the company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at $38,000. Providence Capital Advisors LLC acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at $49,000. Finally, Asset Planning Services Ltd. acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at $55,000. 53.70% of the stock is owned by institutional investors and hedge funds.

BHC has been the topic of several recent research reports. Barclays set a $28.00 price target on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Monday, July 8th. Cantor Fitzgerald set a $32.00 price objective on shares of Bausch Health Companies and gave the stock a “buy” rating in a research note on Friday, May 31st. Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a research note on Monday, July 15th. ValuEngine raised shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research note on Monday, July 29th. Finally, HC Wainwright lifted their target price on shares of Bausch Health Companies from $50.00 to $54.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $29.68.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Further Reading: What is Call Option Volume?

Insider Buying and Selling by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.